JITTERBIT
9.11.2021 09:02:10 CET | Business Wire | Press release
Jitterbit, the API transformation company, has revealed its first ever Integration Trends Report. It gives an unparalleled view of how companies responded to the seismic challenges of the global pandemic - and how they are building back stronger.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005727/en/
Analysing anonymised data of over 2,000 customers across EMEA from 2020 - 2021, the report reveals macro trends across markets as companies innovated to meet rapidly changing customer needs, move more of their services online and enable remote working for employees.
“The trends emerging all point to a need to move quickly and provide the highest level of product, service and employee experience in order to compete and survive, with companies turning to no-code/ low-code and microservices in readiness for the next stage of hypergrowth. ” said Steve Sichtman, VP Multi Channel Development, Jitterbit
Rather than freeze or reduce spend on integrating new technologies, companies actively sought to spend more on integration across a number of key areas:
Service Experience and eCommerce Spend
- With many physical locations closed or severely disrupted in 2020 and unprecedented customer demand for online service, companies responded by increasing their eCommerce integration investment by 99% during the year.
- Companies increased spend on Services Experience 360 on average by 50% in 2020. Growth in the services front-end with applications such as BMC Helix ITSM, Jira, Zendesk and others was also matched with growth in the services back-end around IT operations.
Product Experience
- Companies increased their spend on Product 360 (optimizing the product life cycle) in 2020 by 26%.
- Data from 2020 reveals a double digit increase in demand around large ERP systems from vendors like SAP and Microsoft. Optimizing business processes was a key focus as businesses realized the essential value of having automated processes across the entire manufacturing, supply chain and sales processes.
Employee Experience
- Companies increased their spend on Employee Experience 360 in 2020 by 72%. Increased reliance on a remote workforce, new communications tools, and fluctuating budgets all contributed to this increased focus on employee experience.
Low-code, microservice and marketplace popularity
- Low-code and no-code gained popularity because of the many hyper automation benefits it offers to IT teams, becoming in the process a key differentiator when selecting an integration platform-as-a-service (iPaaS).
- Many companies have already moved to microservices, rather than API, architecture. Self-contained and ready to go, microservices can be plugged into a wide array of applications and leveraged throughout an organization. Now, there’s evidence of increased demand for iPaaS systems that work closely with microservices. This empowers business users to plug different microservices together to create specialized applications without no-code.
- Many Enterprise and Software companies are finding it’s no longer sufficient to offer an API for the outside world to connect to them. They must overcome the “integration burden” to improve retention and stickiness. The answer lies in integration marketplaces where companies can offer pre-built and certified API integrations and solutions to their partners and customers.
This Integration Trends report demonstrates how trends in integration technology - the way modern businesses automate the connections between the myriad softwares, platforms and technologies they deploy - reflect how businesses respond to meet the macro challenges and opportunities they face.
The report also provides actionable insights on what businesses now need to focus on as countries across EMEA move into the post-pandemic period.
To download the full report, visit: https://info.jitterbit.com/jitterbit-trends-report.html
Ends.
About Jitterbit, Inc.
Jitterbit, the API transformation company, makes it quicker and easier for businesses to exploit data from any source, empowering them to rapidly innovate and make faster, more effective decisions. The Jitterbit Harmony API integration platform and API360 solutions enable companies to quickly connect SaaS, on-premises, and cloud applications and instantly infuse intelligence into any business process. To learn more, visit www.jitterbit.com or follow us on LinkedIn and on Twitter at @Jitterbit .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005727/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom